Johnson & Johnson vs Teladoc Health Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Teladoc Health Inc trades at $5.79 (market cap $1.01B). The key difference: Johnson & Johnson is far larger — about 612× Teladoc Health Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Teladoc Health Inc for 39 Days on average.
| JNJ | TDOC | |
|---|---|---|
Market Cap | $618.09B | $1.01B |
Volume | 6,050,983 | 4,668,477 |
Sector | Health | Health |
52-Week High | $278.43 | $9.72 |
52-Week Low | $186.00 | $4.47 |
Typical Hold Time | 129 Days | 39 Days |
Enterprise Value | $646.37B | $1.27B |
Dividend Yield | 2.09% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Teladoc Health (TDOC) trades at $5.77, up 3.78% today but remains near multi-year lows amid ongoing profitability challenges. The stock shows bearish technical signals with mixed earnings performance, having beaten estimates in two of the last three quarters but posting consistent net losses. Recent management changes include the appointment of a new CFO and legal officer as the company focuses on stabilizing its integrated care business while grappling with BetterHelp segment weakness.
While TDOC trades at discounted valuation multiples (P/S 0.4x, P/B 0.77x) and analysts maintain a $8.83 price target, the path to profitability remains uncertain given seven consecutive quarters of negative earnings. The primary investment thesis hinges on the company's ability to monetize its chronic care platform and achieve sustainable free cash flow generation, though investor sentiment remains cautious amid ongoing losses and competitive pressures in virtual healthcare.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →